AVALON PHARMA

06 May, 2024 09:08

Middle East Pharmaceutical Industries Company “Avalon Pharma” announces the approval of the Saudi Food and Drug Authority (SFDA) to register new production lines at the company's Factory No. 2 in Riyadh

Element ListExplanation
Announcement Detail Middle East Pharmaceutical Industries Company "Avalon Pharma" is pleased to announce the approval of the Saudi Food and Drug Authority (SFDA) for the registration of new production lines at the company's Plant No. (2) in Riyadh city. The newly approved production lines include lines for capsules and tablets, as well as semi-solids, including creams, ointments, and gels. When fully operational, the newly registered lines will have a production capacity of 270 million tablets and capsules per year, while semi-solids will have a production capacity of 22 million units per year. Commercial production will commence on the new production lines upon obtaining the necessary approvals from the Saudi Food and Drug Authority (SFDA) relevant to the targeted products. For more information, please contact the company's Investor Relations Department at investors.relations@avalon.com.sa

Other Announcements

ALHAMMADI
2024-05-19

Correction announcement from Al Hammadi Holding in regards to Interim Financial results for the Period Ending on 2024-03-31 ( Three Months )

Read More
JAZADCO
2024-05-19

Jazan Development and Investment Co. announces its Interim Financial results for the Period Ending on 2024-03-31 ( Three Months )

Read More
AVALON PHARMA
2024-05-19

Middle East Pharmaceutical Industries Co. announces its Interim Financial results for the Period Ending on 2024-03-31 ( Three Months )

Read More